Pacific Biosciences
PACB
101 hedge funds and large institutions have $342M invested in Pacific Biosciences in 2014 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 31 increasing their positions, 27 reducing their positions, and 10 closing their positions.
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
113% more call options, than puts
Call options by funds: $540K | Put options by funds: $253K
93% more capital invested
Capital invested by funds: $178M → $342M (+$164M)
15% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 27
15% more funds holding
Funds holding: 88 → 101 (+13)
Top Buyers
| 1 |
DM
Deerfield Management
New York
|
+$4.62M |
| 2 |
BG
BlackRock Group
London,
United Kingdom
|
+$4.13M |
| 3 |
D.E. Shaw & Co
New York
|
+$3.16M |
| 4 |
Millennium Management
New York
|
+$1.82M |
| 5 |
IG
ING Group
Amsterdam,
Netherlands
|
+$1.6M |
Top Sellers
PACB Hedge Fund Activity: Q4 2014 in Review
101 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2014, worth a combined $342M — up 93% from $178M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new PACB positions and 10 closed out — a net gain of 15 holders — while 31 added to existing stakes and 27 trimmed.
The largest buyer was Deerfield Management, adding an estimated $4.62M. The largest seller was Raging Capital Management, exiting entirely with an estimated $7.75M sold.
- 101 institutional investors held Pacific Biosciences (PACB) as of Q4 2014, up from 88 in Q3 2014.
- Funds reported $342M of Pacific Biosciences stock for Q4 2014, up 93% quarter-over-quarter.
- 25 funds opened new Pacific Biosciences positions in Q4 2014 and 10 closed out, a net change of +15 holders.
- The largest Pacific Biosciences buyer in Q4 2014 was Deerfield Management, an estimated $4.62M added.
- The largest Pacific Biosciences seller in Q4 2014 was Raging Capital Management, an estimated $7.75M sold.
Based on aggregated 13F filings for Q4 2014.